MCID: MLG065
MIFTS: 36

Malignant Fibroxanthoma

Categories: Cancer diseases

Aliases & Classifications for Malignant Fibroxanthoma

MalaCards integrated aliases for Malignant Fibroxanthoma:

Name: Malignant Fibroxanthoma 12 14
Fibrous Histiocytoma, Malignant 12
Histiocytoma, Malignant Fibrous 42
Malignant Fibrous Histiocytoma 69
Fibroxanthosarcoma 12
Mfh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1907
MeSH 42 D051677
NCIt 47 C4247
UMLS 69 C0334463

Summaries for Malignant Fibroxanthoma

MalaCards based summary : Malignant Fibroxanthoma, also known as fibrous histiocytoma, malignant, is related to inflammatory mfh and malignant skin fibrous histiocytoma. An important gene associated with Malignant Fibroxanthoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Inhibition of Ribosome Biogenesis by p14(ARF) and Signaling events mediated by HDAC Class III. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and testes, and related phenotypes are neoplasm and no phenotypic analysis

Related Diseases for Malignant Fibroxanthoma

Diseases related to Malignant Fibroxanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Related Disease Score Top Affiliating Genes
1 inflammatory mfh 11.9
2 malignant skin fibrous histiocytoma 11.2
3 undifferentiated pleomorphic sarcoma 11.2
4 early invasive cervical adenocarcinoma 10.8 LYZ SERPINA1
5 acromegaly 10.7 LYZ SERPINA3
6 macular dystrophy, patterned, 1 10.7 LYZ SERPINA1
7 arteriosclerosis 10.7 SERPINA1 SERPINA3
8 inferolateral myocardial infarct 10.7 MB SERPINA1
9 bile duct sarcoma 10.6 MB MYOD1
10 rnase t2-deficient leukoencephalopathy 10.6 MDM2 TP53
11 spleen cancer 10.6 MB MYOD1
12 acute cholinergic dysautonomia 10.6 MDM2 TP53
13 mucinous ovarian cystadenoma 10.6 MB MYOD1
14 cystic kidney disease 10.6 LYZ TP53
15 rectum squamous cell carcinoma 10.6 MDM2 TP53
16 adult central nervous system germinoma 10.6 LYZ PTPRC
17 lichen nitidus 10.6 MDM2 TP53
18 rhabdoid cancer 10.6 LYZ SERPINA1 SERPINA3
19 lateral medullary syndrome 10.5 MB MYOD1
20 posterior uveitis 10.5 CD68 SERPINA1
21 lung benign neoplasm 10.5 MB PTPRC
22 esophageal adenosquamous carcinoma 10.5 LYZ PTPRC
23 urethral urothelial papilloma 10.5 CD68 LYZ
24 rhabditida infections 10.5 MDM2 PTPRC
25 gigantism 10.5 CD68 MB
26 tropical spastic paraparesis 10.5 CD68 LYZ
27 coronary aneurysm 10.5 MDM2 PTPRC
28 group b strep disease in newborns 10.5 SERPINA1 TP53
29 visual snow syndrome 10.5 CD68 MB
30 breast epithelioid hemangioma 10.5 MDM2 TP53
31 localized osteosarcoma 10.5 MDM2 MYOD1
32 aniseikonia 10.5 CD68 SERPINA1
33 cutaneous ganglioneuroma 10.5 CD68 SERPINA1
34 glomerulonephritis 10.5 MB MYOD1
35 secondary pulmonary hemosiderosis 10.5 MDM2 TP53
36 fibrous histiocytoma 10.5
37 sleep disorder 10.5 MDM2 SERPINA1 SERPINA3
38 pneumocystosis 10.5 CD68 SERPINA1
39 pigmented villonodular synovitis 10.5 CD68 LYZ
40 laryngitis 10.5 CD68 LYZ
41 ascaridiasis 10.5 MDM2 TP53
42 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.4 MB TP53
43 lymphopenia 10.4 MDM2 TP53
44 sparse hair ptosis mental retardation 10.4 MDM2 TP53
45 childhood spinal cord tumor 10.4 PTPRC TP53
46 ritter's disease 10.4 CD68 TP53
47 neurofibroma of the esophagus 10.4 CD68 MDM2
48 primary pulmonary lymphoma 10.4 MDM2 MYOD1 SERPINA3
49 granular cell leiomyosarcoma 10.4 CD68 MYOD1
50 filamentary keratitis 10.3 CD68 PTPRC

Graphical network of the top 20 diseases related to Malignant Fibroxanthoma:



Diseases related to Malignant Fibroxanthoma

Symptoms & Phenotypes for Malignant Fibroxanthoma

MGI Mouse Phenotypes related to Malignant Fibroxanthoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.63 FOXO4 LYZ MDM2 MYOD1 PTPRC TP53
2 no phenotypic analysis MP:0003012 9.43 CD68 LYZ MDM2 MYOD1 PTPRC TP53
3 skeleton MP:0005390 9.17 PTPRC TP53 CD68 CREB3L2 LYZ MDM2

Drugs & Therapeutics for Malignant Fibroxanthoma

Drugs for Malignant Fibroxanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Lenograstim Approved Phase 3 135968-09-1
10
Dactinomycin Approved Phase 3 50-76-0 2019 457193
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
16 Isophosphamide mustard Phase 3,Phase 2,Phase 1
17 Alkylating Agents Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Antiviral Agents Phase 3,Phase 2,Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
24 Etoposide phosphate Phase 3,Phase 2
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Antirheumatic Agents Phase 3,Phase 2,Phase 1
27 Antimitotic Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
29 Antimetabolites Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
32
Indinavir Approved Phase 2 150378-17-9 5362440
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
35
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
36
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
37
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
38
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
39
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
40
nivolumab Approved Phase 1, Phase 2 946414-94-4
41
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
42
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
43
Bevacizumab Approved, Investigational Phase 2 216974-75-3
44
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
45
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
46
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
48
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
49
Camptothecin Experimental Phase 2 7689-03-4
50 Exatecan Investigational Phase 2 171335-80-1

Interventional clinical trials:

(show top 50) (show all 59)

id Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
23 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
24 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
25 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
26 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
27 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
28 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
29 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
31 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
32 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
35 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
36 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
37 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
38 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
39 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
40 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
41 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
42 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
43 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2 Alisertib
44 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
45 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Suspended NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
46 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
47 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Gemcitabine and Docetaxel in Combination with Pazopanib
48 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
49 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride

Search NIH Clinical Center for Malignant Fibroxanthoma

Cochrane evidence based reviews: histiocytoma, malignant fibrous

Genetic Tests for Malignant Fibroxanthoma

Anatomical Context for Malignant Fibroxanthoma

MalaCards organs/tissues related to Malignant Fibroxanthoma:

39
Bone, Lung, Testes, Liver, Endothelial, Brain

Publications for Malignant Fibroxanthoma

Articles related to Malignant Fibroxanthoma:

id Title Authors Year
1
Malignant fibroxanthoma: a sarcoma of the vulva. ( 4704007 )
1973
2
Fibrosarcoma (malignant fibroxanthoma) involving conjunctiva and ciliary body. ( 5053693 )
1972
3
Ultrastructure of a fibroxanthosarcoma (malignant fibroxanthoma). ( 4105302 )
1971
4
Malignant fibroxanthoma (malignant histiocytoma): an ill-defined histologic entity with unpredictable biologic behavior. Report of a case with long-term survival. ( 4248417 )
1970
5
Metastasizing retroperitoneal fibroxanthoma (malignant fibroxanthoma). ( 5506607 )
1970

Variations for Malignant Fibroxanthoma

Copy number variations for Malignant Fibroxanthoma from CNVD:

7 (show all 41)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18958 1 148000000 153300000 Gain Malignant fibrous histiocytomas
2 27753 1 212100000 222100000 Loss Malignant fibrous histiocytomas
3 33593 1 46500000 56200000 Gain Malignant fibrous histiocytomas
4 35188 1 60900000 69500000 Gain Malignant fibrous histiocytomas
5 37769 1 94500000 99400000 Gain Malignant fibrous histiocytomas
6 39415 10 114900000 121700000 Loss Malignant fibrous histiocytomas
7 50207 11 115400000 134452384 Loss Malignant fibrous histiocytomas
8 59633 11 76700000 85300000 Loss Malignant fibrous histiocytomas
9 60562 11 87900000 96700000 Loss Malignant fibrous histiocytomas
10 69083 12 5300000 14800000 Gain Malignant fibrous histiocytomas
11 76673 13 34700000 48900000 Loss Malignant fibrous histiocytomas
12 78011 13 48900000 57600000 Loss Malignant fibrous histiocytomas
13 86677 14 64000000 88900000 Gain Malignant fibrous histiocytomas
14 88587 14 92800000 106368585 Gain Malignant fibrous histiocytomas
15 101715 16 45500000 54500000 Loss Malignant fibrous histiocytomas
16 103579 16 6300000 10300000 Loss Malignant fibrous histiocytomas
17 107007 17 11200000 15900000 Gain Malignant fibrous histiocytomas
18 107027 17 11200000 22100000 Gain Malignant fibrous histiocytomas
19 107535 17 15900000 22100000 Gain Malignant fibrous histiocytomas
20 112060 17 37800000 44800000 Gain Malignant fibrous histiocytomas
21 119810 18 17300000 23300000 Gain Malignant fibrous histiocytomas
22 122735 18 59800000 76117153 Loss Malignant fibrous histiocytomas
23 127802 19 37100000 47800000 Gain Malignant fibrous histiocytomas
24 134297 2 1 12800000 Loss Malignant fibrous histiocytomas
25 142547 2 225800000 237000000 Loss Malignant fibrous histiocytomas
26 154853 20 49200000 54400000 Gain Malignant fibrous histiocytomas
27 163375 22 27900000 35900000 Gain Malignant fibrous histiocytomas
28 163745 22 30500000 39300000 Gain Malignant fibrous histiocytomas
29 164763 22 39300000 49691432 Loss Malignant fibrous histiocytomas
30 178974 3 83700000 89400000 Gain Malignant fibrous histiocytomas
31 187572 4 52400000 59200000 Gain Malignant fibrous histiocytomas
32 192956 5 121500000 143100000 Loss Malignant fibrous histiocytomas
33 198017 5 18500000 23300000 Gain Malignant fibrous histiocytomas
34 214607 6 63500000 75900000 Gain Malignant fibrous histiocytomas
35 221899 7 147500000 158821424 Loss Malignant fibrous histiocytomas
36 225328 7 4500000 7200000 Gain Malignant fibrous histiocytomas
37 226671 7 61100000 71800000 Gain Malignant fibrous histiocytomas
38 237234 8 2200000 19100000 Loss Malignant fibrous histiocytomas
39 244141 8 93500000 99100000 Gain Malignant fibrous histiocytomas
40 250775 9 2200000 9000000 Loss Malignant fibrous histiocytomas
41 255895 9 86100000 113900000 Gain Malignant fibrous histiocytomas

Expression for Malignant Fibroxanthoma

Search GEO for disease gene expression data for Malignant Fibroxanthoma.

Pathways for Malignant Fibroxanthoma

Pathways related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.5 MDM2 TP53
2 10.39 FOXO4 MYOD1 TP53
3
Show member pathways
10.3 MDM2 TP53

GO Terms for Malignant Fibroxanthoma

Biological processes related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.65 CREB3L2 FOXO4 MYOD1 TAF6 TP53
2 neutrophil degranulation GO:0043312 9.55 CD68 LYZ PTPRC SERPINA1 SERPINA3
3 regulation of signal transduction by p53 class mediator GO:1901796 9.5 MDM2 TAF6 TP53
4 positive regulation of cell cycle arrest GO:0071158 9.43 FOXO4 TP53
5 cellular response to gamma radiation GO:0071480 9.4 MDM2 TP53
6 positive regulation of protein export from nucleus GO:0046827 9.37 MDM2 TP53
7 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
8 response to water-immersion restraint stress GO:1990785 8.62 FOXO4 MDM2

Molecular functions related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.26 FOXO4 MDM2 MYOD1 TP53
2 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.16 MYOD1 TP53
3 identical protein binding GO:0042802 9.02 FOXO4 LYZ MDM2 SERPINA1 TP53

Sources for Malignant Fibroxanthoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....